Amneal Pharmaceuticals, Inc.

NASDAQ:AMRX

Drug Manufacturers - Specialty & Generic

Healthcare
$21.88 -0.90%

-$0.15 today

Market cap
$7.62B
Beta
1.32
P/E (TTM)
43.4
EPS (TTM)
$0.37
52W Low $7.67High $16.61

Volume 1.91M

Average 1.75M

AMRX Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Amneal Pharmaceuticals, Inc.NASDAQ: AMRX

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin widens to 42.0%

Gross margin was 42.0% in Q2 FY2026, up 2.5 pp from a year earlier. On a trailing-twelve-month basis it was 39.3%, up 1.7 pp year over year. Over 3 fiscal years it widened by 1.9 pp.

Context

  • Gross margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
42.0%-2.3 pp QoQ
Last fiscal yearDec 2025
37.6%+1.1 pp YoY
LTMJun 2026
39.3%+1.7 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+2.5 pp——
1 year+1.1 pp——
3 years+1.9 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
37.6%
Year-over-year change
+1.1pp

Gross Margin vs competitors

How AMRX compares with its peers on the latest reported figures

  • AMRX's LTM Jun 2026 gross margin of 39.3% is the 9th highest of the 11 companies compared; the peer median is 51.0%.
  • Its year-over-year change of +1.7 pp is the 4th highest of 11, against a peer median of -0.8 pp.
  • Over three fiscal years its change of +1.9 pp compares with a peer median of -0.3 pp.
AMRX Competitors Peer median
Gross Margin for AMRX and competitors
Company Period LTM level YoY 3-year change
INDVIndivior Pharmaceuticals IncLTM Jun 202683.9% -0.1 pp-3.1 pp
CPIXCumberland Pharmaceuticals Inc.LTM Mar 202682.9% -1.4 pp+6.7 pp
BHCBausch Health Companies Inc.LTM Jun 202671.8% +1.1 pp-0.3 pp
ANIPANI Pharmaceuticals, Inc.LTM Mar 202665.9% +6.6 pp-5.1 pp
TEVATeva Pharmaceutical Industries LimitedLTM Jun 202652.5% +2.9 pp+5.1 pp
RDYDr. Reddy's Laboratories LimitedLTM Sep 202649.5% -7.0 pp-3.9 pp
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 202647.3% -3.3 pp-0.4 pp
EBSEmergent BioSolutions Inc.LTM Mar 202644.4% +8.0 pp+4.9 pp
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 202639.3% +1.7 pp+1.9 pp
VTRSViatris Inc.LTM Jun 202634.8% -1.8 pp-4.9 pp
PRGOPerrigo Company plcLTM Jun 202633.3% -2.5 pp+2.4 pp
Peer median (excluding AMRX) 51.0%-0.8 pp-0.3 pp

Competitors are the stored peer set for AMRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.09B2.21B2.39B2.79B3.02B
Cost of Revenue1.32B1.42B1.53B1.77B1.88B
Gross Profit768.97M791.46M863.87M1.02B1.14B
Gross Margin36.7%35.8%36.1%36.5%37.6%
Research & Development209.56M208.66M194.75M190.71M186.18M
Selling, General & Admin365.5M399.7M429.68M476.44M526.83M
Operating Expenses616.26M886.39M659.5M771.11M713M
Depreciation & Amortization233.41M240.18M229.4M236.19M223.57M
EBITDA401.1M440.21M500.78M439.77M603.87M
EBITDA Margin19.2%19.9%20.9%15.7%20.0%
Operating Income152.72M(94.93M)204.37M249.33M423.09M
Operating Margin7.3%-4.3%8.5%8.9%14.0%
Interest Income00000
Interest Expense136.33M158.38M210.63M258.6M241.09M
Other Income / Expenses(121.35M)(153.2M)(244.64M)(304.34M)(283.88M)
Income Before Tax31.37M(248.13M)(40.27M)(55.01M)139.21M
Pre-Tax Margin1.5%-11.2%-1.7%-2.0%4.6%
Income Tax Expense11.2M6.66M8.45M18.86M11.28M
Net Income10.62M(129.99M)(83.99M)(116.89M)72.06M
Net Margin0.5%-5.9%-3.5%-4.2%2.4%
EPS (Basic)0.07(0.86)(0.48)(0.38)0.23
EPS (Diluted)0.07(0.86)(0.48)(0.38)0.22
Weighted Avg Shares148.92M150.94M174.99M308.98M313.37M
Weighted Avg Shares (Diluted)151.82M150.94M176.14M308.98M324.81M

Amneal Pharmaceuticals, Inc.

NASDAQ:AMRX

Intrinsic Alpha fair value

Locked

Current Price

$21.88

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.